title: Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
abstract: Prognosis and survival of patients with hepatocellular carcinoma (HCC) is still very poor, and no therapies are currently available to inhibit tumour growth and metastases. Recently, we reported that the expression of an extracellular matrix component (ECM), namely Laminin-5 (Ln-5), is directly related to poor prognosis in HCC patients. The aim of our study is to investigate the preclinical effect of gefitinib in an in vitro HCC model. We found that the IC(50) of gefitinib in HCC cells ranged from 0.7 to 10.0 muM, whereas Ln-5 inhibited the activity of gefitinib in a dose-dependent manner. Complete inhibition of phosphorylated (p)-EGFR (epidermal growth factor receptor) was obtained within 6 h exposure to gefitinib and complete restoration of the receptor status was obtained after 24 h. A downstream effect yields a decrease in p-Akt and p-Erk 1/2. The addition of exogenous Ln-5 has no effect on p-EGFR, whereas it restores p-Erk 1/2 and p-Akt. Consistently, Ln-5 induces recovery of HCC cells from Gefitinib-induced apoptosis. In conclusion, gefitinib inhibits HCC cell growth and we report for the first time that Ln-5, but not other ECM molecules, reduces the ability of gefitinib to inhibit cell growth via Akt. As patients with HCC have different Ln-5 expression levels, these results may help to better understand which patients might benefit from gefitinib treatment.
authors.affiliation: Section of Internal Medicine, Department of Internal Medicine, Immunology, and Infectious Diseases, University of Bari Medical School, Bari, Italy. g.giannelli@intmed.uniba.it
authors.forename: G
authors.initials: G
authors.lastname: Giannelli
authors.forename: A
authors.initials: A
authors.lastname: Azzariti
authors.forename: E
authors.initials: E
authors.lastname: Fransvea
authors.forename: L
authors.initials: L
authors.lastname: Porcelli
authors.forename: S
authors.initials: S
authors.lastname: Antonaci
authors.forename: A
authors.initials: A
authors.lastname: Paradiso
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D000077156:Gefitinib; D006801:Humans; D010766:Phosphorylation / Q000187:drug effects; D011237:Predictive Value of Tests; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D011799:Quinazolines / Q000627:therapeutic use*; D000097794:Kalinin
chemical_list: D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; D066246:ErbB Receptors; D000077156:Gefitinib; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D011799:Quinazolines; D000097794:Kalinin; C494918:AKT1 protein, human